Skip to contentK
Korro Bio, Inc.
K
KRROKorro Bio, Inc. Q1 2025 · 10-Q
Revenue$2.55M$2.55M— vs Q1 2024 Net Income-$23.39M-$23.39MN/M vs Q1 2024 EPS Diluted-$2.49-$2.49N/M vs Q1 2024 Operating Income-$25,020,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Korro Bio, Inc. · CIK 1703647 · Engraved from SEC EDGAR
Free Cash Flowderived-$24,571,000N/M Margins · derivedOperating margin-981.2%
Net margin-917.1%
ended Mar 31, 2025 · filed May 7, 2025 · 37 d after period end